Table 1.
|
Group I |
Group II |
p -value* |
|||
---|---|---|---|---|---|---|
T0 | T6 | T12 | T72 | |||
Males |
32 (88.9) |
- |
- |
- |
17 (77.3) |
- |
Age (years) |
39 (35–45) |
- |
- |
- |
38 (33–43) |
- |
Risk factors for HIV-1: |
|
|
|
|
|
|
· Heterosexual |
20 (55.6) |
- |
- |
- |
7 (31.8) |
- |
· Homo/bisexual |
10 (27.8) |
- |
- |
- |
10 (45.5) |
- |
· IVDU |
3 (8.3) |
- |
- |
- |
5 (22.7) |
- |
Other/unknown |
3 (8.3) |
- |
- |
- |
0 (0) |
- |
CD4+ T cells (cells/μL) |
258 (139–331) |
377 (225–505) |
419 (247–570) |
688 (407–822) |
538 (455–691) |
<0.0001 |
CD8+ T cells (cells/μL) |
754 (637–1338) |
781 (598–990) |
753 (561–983) |
707 (598–805) |
757 (595–1138) |
- |
CD4+/CD8+ T-cell ratio |
0.3 (0.2–0.4) |
0.5 (0.3–0.7) |
0.6 (0.4–0.7) |
0.8 (0.6–1.1) |
0.7 (0.5–1) |
<0.0001 |
HIV-1 RNA (copies/mL) | 74533 (21264–196233) | < 50 (50–50) | < 50 (50–50) | < 37 (37–37) | 14155 (263–33380) | <0.01 |
For continuous variables the medians (interquartile ranges) are shown, while for categorical variables the number (percentage) is shown.
Group I, HIV-1-infected patients enrolled in the SI.S.THER. study; group II, HIV-1-infected patients naive to antiretroviral therapy.
IVDU indicates Intravenous Drug Users.
*p -value of the comparison between group I at T0 and group II.